Clinical Roundup Rural cancer patients do just as well as urban patients when having surgery close to home, study finds February 13, 2026Vol.52 No.06
Clinical Roundup AI tool may help personalize ovarian cancer treatment from day one February 13, 2026Vol.52 No.06
Clinical Roundup HPV cancer vaccine slows tumor growth, extends survival in animal models February 13, 2026Vol.52 No.06
Clinical Roundup Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology February 13, 2026Vol.52 No.06
Drugs & Targets FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma February 13, 2026Vol.52 No.06
Drugs & Targets FDA approves companion diagnostic for pembrolizumab for ovarian cancer February 13, 2026Vol.52 No.06
Conversation with The Cancer Letter On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center February 06, 2026Vol.52 No.05By Paul Goldberg
NCI Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural researchThe group replaced the NCI Board of Scientific Advisors February 06, 2026Vol.52 No.05By Claire Marie Porter
Capitol Hill After a brief government shutdown, FY26 funding bill is signed into lawNIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored February 06, 2026Vol.52 No.05By Jacquelyn Cobb
Guest Editorial The National Highway Traffic Safety Administration has a profound, albeit not immediately obvious, impact on cancer February 06, 2026Vol.52 No.05By Ken Kobayashi and Joan H. Schiller
